Recent publications

  • Barriers to healthcare access during pregnancy and after birth for adolescent girls living with disability in Sierra Leone: a qualitative study

    Kamara, P, Kamara, M, November, L, Sandall, J, Williams, P.T, , Wurie, H, Fernandez-Turienzo, C.
    BMJ Open
    Published June 2026.
    Objective: In 2017, Lifeline Nehemiah Projects in Sierra Leone launched 2YoungLives, a mentoring initiative for vulnerable pregnant adolescents, including those living with disabilities. Drawing from the social model of disability, we aimed to investigate the exacerbated disabling barriers which prevent these girls and their babies from accessing available healthcare and develop comprehensive solutions to improve their access.

  • A Global scoping review of of community-based mentoring interventions for adolescent girls during pregnancy and after birth.

    Fernandez-Turienzo, C, Kamara, M, November, L, Kamara, P, De Backer, K, Rayment-Jones, H, Kingsford, A, Williams, P.T, Sandall, J.
    Journal of Global Health
    Published June 2026.
    Objective: For pregnant adolescents, youth mentoring interventions show promise in improving health and well-being outcomes. However, existing studies largely exclude this population group. To address this gap, we conducted a global scoping review of community-based mentoring interventions for adolescent girls during pregnancy and after birth.

  • Strengthening global pre-eclampsia diagnosis: the potential role of biomarkers in low-income and middle-income countries

    Samuels, L, Mukape, M, Kurt, K, De Oliveira, L, Shennan, A, Chappell, L, Hurrell, A.
    The Lancet
    Published May 2026.
    Objective: This Review summarises evidence on pre-eclampsia diagnosis in LMICs, including biomarker performance, emerging low-cost and point-of-care approaches, and areas of opportunity in low-resource environments, where the potential for benefit is greatest. Harnessing these diagnostics could enhance pre-eclampsia detection, support timely intervention, and ultimately reduce preventable deaths among women and babies.

  • Assessment of point-of-care creatinine testing in pregnancy: a prospective cohort study in Sierra Leone

    Kurt, K, Cole, R, Squire, C, Kamara, A, Ganyaglo, G, Coker, J, Clark, K, Beardmore-Gray, A, Ridout, A, Fernandez Turienzo, C, Campbell, J, Adeniji, A, Shennan, A, Bramham, K.
    The Lancet
    Published May 2026.
    Objective: We aimed to describe the incidence, resolution, and clinical consequences of presumed PrAKI or kidney dysfunction among high-risk pregnant and postpartum women, and to assess feasibility of POC-Cr testing.

  • Planned early birth versus expectant management for hypertensive disorders from 34 weeks' gestation to term

    Beardmore-Gray, A, Rohwer, C, Fernandez Turienzo, C, Cluver, C.
    PLOS Medicine
    Published May 2026.
    Objective: To assess the benefits and risks of planned early birth versus expectant management in pregnant women with hypertensive disorders, from 34 weeks' gestation onwards.

  • Prediction of severe maternal and perinatal complications in hypertensive pregnancies using point-of-care glycosylated fibronectin: A prospective cohort study

    Martin, A, Seed, P, Kuhrt, K, Bramham, K, Shennan, A.
    Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
    Published March 2026.
    Objective: To evaluate the test accuracy of glycosylated fibronectin (GlyFn) to predict adverse maternal and neonatal outcomes in women with hypertensive pregnancies in a low resourced setting.

  • A global Consortium for pregnancy-associated acute kidney injury

    Clark, K, Kuhrt, K, Beardmore-Gray, A, Shemies, R, Chanda, K, Bramham, K, Global PrAKI consortium attendees.
    The Lancet, Obstetrics, Gynaecology & Women's Health
    Published January 2026.
    Objective: Pregnancy-associated acute kidney injury (PrAKI) is an under-recognised contributor to maternal and perinatal morbidity and mortality, with incidence up to 30 times higher in low-income and middle-income countries than in high-income settings. In May 2025, the World Health Assembly adopted the first resolution on kidney disease, recognising it as a global public health priority and calling for strengthened prevention, early detection, and equitable access to care across the life course, including in pregnancy. The Global PrAKI Consortium and integrated Academy was established at an international stakeholder workshop in Nairobi, Kenya, in July 2025, with the aims to improve prevention, recognition, and management of PrAKI through research and education and to co-design practical tools and define a near-term pathway from evidence to service change.

  • FemTech and the future of women's health: from innovation to equity

    Ridout, A, Shennan, A, Oteng-Intim, E.
    The Lancet, Obstetrics, Gynaecology & Women's Health
    Published January 2026.
    Objective: This Viewpoint outlines the evolution of FemTech, and highlights the impact of low-cost, locally adapted tools. It explores how innovations designed for low-resource settings are influencing practices in high-income countries, through bidirectional learning. We argue that FemTech must address the systemic barriers that continue to limit progress and present a pathway forward, centred on lived experience and co-design. At its best, FemTech can be a catalyst for reshaping how health care is delivered, and whose voices shape it. The stakes are high, not just for women's health, but for global development..

  • Evaluating shock index for prediction of adverse maternal outcomes related to postpartum haemorrhage and maternal sepsis in Sierra Leone: a prospective observational cohort study

    Khurt, K, Janneh, F, Cole, R, Ridout, A, Fernandez-Turienzo, C, Seed, P, Bramham, K, Shennan, A.
    eClinical Medicine
    Published November 2025.
    Objective: Postpartum haemorrhage (PPH) and sepsis account for more than half of global maternal deaths. Shock index (SI), the ratio of heart rate to systolic blood pressure, has shown superior prediction of adverse outcomes compared to other vital signs, but most studies are retrospective, with limited evidence in sepsis. We aimed to prospectively evaluate SI for adverse outcome prediction in PPH and sepsis.

  • Evaluating the real-world scale-up of the CRADLE Vital Signs Alert intervention into routine maternity care in Sierra Leone (CRADLE 5): a stepped-wedge, type 2 hybrid implementation-effectiveness, cluster-randomised controlled trial

    Ridout, A,, Moses, F, Herm-Singh, S, Beoku-Betts, C, Businge, E, Fernandez-Turienzo, C, Goodhart, V, Hurrell, A, Kamara, D, Kamara, J, Koroma, K, Kuhrt, Martin, Momah, M, Seed, P, Sam, B, Samura, S, Williams, P, Chappell, L, Smart, F, Sesay, T, Kenneh S, Sandall, J, Gevoa, S, Shennan, A, on behalf of CRIBS CollaborativeGroup.
    Lancet Global
    Published October 2025.
    Objective: Sierra Leone has one of the highest maternal mortality ratios globally. Most preventable maternal deaths result from haemorrhage, hypertension, or sepsis, yet many facilities do not have the basic tools for vital sign monitoring. This study evaluated whether national scale-up of the CRADLE intervention (a vital signs device with a traffic-ight early warning system) could reduce adverse maternal and perinatal outcomes and be sustainably integrated into routine care

  • Point-of-Care Placental Growth Factor for Predicting Adverse Outcomes in Sierra Leone

    Kuhrt, K, Cole, R, M’Bayoh,M, Mabula-Bwalya, C, Hurrell,A, Ridout, A, Fernandez-Turienzo, C, Seed, P, Chappell, L, Bramham, K, Shennan, A, Pineapple Study Group.
    Hypertension
    Published October 2025.
    Objective: Placental growth factor (PlGF) concentrations are lower in preeclampsia, a major cause of maternal death; testing improves diagnosis and outcomes. We evaluated 2 novel, whole blood, point-of-care PlGF tests (RONIA and Lepzi Quanti) in a low-resource setting for predicting adverse outcomes.

  • Community-based mentoring to reduce maternal and perinatal mortality in adolescent pregnancies in Sierra Leone (2YoungLives): a pilot cluster-randomised controlled trial.

    Fernandez Turienzo, C, November, L, Kamara, M, Conteh, O, Kamarak, P, Kingsford, A, Koroma, P, Munu, M, Ridout, A, Sam, B, Seed, P, Thomas, S, Williams, P, Shennan, A, Sandall, J, on behalf of the CRIBS Collaborative Group†
    Lancet
    Published 18 June 2025
    Objective: Sierra Leone has very high maternal and neonatal mortality rates, and a large proportion of these deaths occur in adolescents, a particularly vulnerable group, and is usually driven by poverty, lack of education, and sparse employment opportunities. We evaluated the feasibility and potential effects of a community-based mentoring intervention from pregnancy up to 1 year after birth to inform a subsequent larger trial aiming to reduce mortality among adolescent girls and their newborns (2YoungLives).

  • The Escalating Inequalities in Global Maternal Mortality—Time to Act: A Commentary

    Martin, A, Ridout, A, Afolabi, B, Shennan, A
    BJOG: An International Journal of Obstetrics & Gynaecology
    Published 13 May 2025.
    Objective: The Escalating Inequalities in Global Maternal Mortality—Time to Act: A Commentary

  • Rule-in and rule-out of pre-eclampsia using a novel point-of-care placental growth factor test

    Rogers, J, Hurrell, A, Sahgal, G, Samuels, L, Mabula-Bwalya, C, Kuhrt, K, Gill, C, Brockbank, A, Dalyrmple, K, De Marvao, A, Seed, P, Chappell, L, Shennan, A, Bramham, K. .
    Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
    Published 10 April 2025.
    Objective: To evaluate test performance of the point-of-care Lepzi® Quanti placental growth factor (PlGF) test to rule-in and rule-out pre-eclampsia at various time points, in women presenting with suspected preeclampsia.

  • Eclampsia among adolescent mothers in low- and middle-Income countries

    Van der Krogt, L, Ridout, A, Vousden, N, Nathan, H, Seed, P, Sam, B, Momoh, M, Sessay, T, Smart, F, Bellad, M, Vwalika, B, Shennan, A.
    PLOS Global Health
    Published 26 March 2025.

    Objective: Hypertensive disorders, including eclampsia, contribute to around 20% of direct maternal deaths, many of which are preventable with simple, cost-effective interventions. This study aims to quantify the risk of eclampsia among adolescent mothers in low- and middle-income countries.

  • Towards person-centred maternal and newborn care in Ethiopia: a mixed method study of satisfaction and experiences of care

    Eshetu, T, Fekadu, E, Abdella, A, Mulushoa, A, Medhin, G, Belina, M, Alem, A, Keynejad, R, Robbins, T, Seward, N, Shennan, A, Howard, L, Prince, M, Sandall, J, Hanlon, C .
    BMC Pregnancy and Childbirth
    Published 30 January 2025.
    Objective: Person-centred maternal care is associated with positive experiences in high-income countries. Little is known about the transferability of this concept to non-Western, low-income settings. We aimed to explore women’s experiences of care and investigate satisfaction with antenatal care (ANC) in relation to person-centred care and unmet psychosocial needs in rural Ethiopia.

  • A novel approach to expedite evidence to impact in pre eclampsia: co developed policy labs in Zambia and Sierra Leone

    Kuhrt, K, Mabula-Bwalya, C, Boulding, H, Beardmore-Gray, A, Ridout, A, Koroma, O, Sam, B, Williams, P, Smart, F, Meleki I, Mwila, M, Chileshe, M, Maweree, R, Hurrell, A, Mbiiza, C, Fernandez-Turienzo, C, Sandall, J, Vwalika, B, , Bramham, K, Shennan, A.
    BMC Global and Public Health
    Published 7 January 2025.
    Objective: We describe co‑development and delivery of policy labs, working with The Policy Institute (King’s College London), and local stakeholders in Sierra Leone and Zambia, to expedite integration of new knowledge into pre‑eclampsia care pathways, to improve care for women and babies with the worst outcomes.

  • Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial

    A Beardmore-Gray, N Vousden, P Seed, B Vwalika, S Chinkoyo, V Sichone, A Kawimbe, U Charantimath, G Katageri, M Bellad, L Lokare, K Donimath, S Bidri, S Goudar, J Sandall, L Chappell, A Shennan, on behalf of the CRADLE-4 Study Group.
    Published 29 June 2023.
    Objective: Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial..

  • Innovations to reduce maternal mortality and improve health and wellbeing of adolescent girls and their babies in Sierra Leone

    C Fernandez Turienzo, L November, M Kamara, P Kamara, V Goodhart, A Ridout, B Sam, S Thomas, P Williams, J Sandall, A Shennan on behalf of CRIBS Collaborative Group.
    Published 25 November 2022.
    Objective: The 2YoungLives community engagement mentoring scheme aims to develop simple, scalable innovations to reduce maternal mortality and build research capacity and expertise in Sierra Leone.

  • Accurate surveillance of maternal deaths is an international priority

    AH Shennan, M Green, AE Ridout.
    Published 16 November 2022.
    Objective: Variations in maternal mortality remain one of the starkest health injustices in the world

  • The neutrophil-to-lymphocyte ratio: A low-cost antenatal indicator of placental chorioamnionitis in women who deliver preterm without clinical signs and symptoms of infection

    AE Ridout, V Horsley, PT Seed, N Simpson, R Tribe, AH Shennan.
    Published 1 November 2022.
    Objective: To explore the relationship between the neutrophil-to-lymphocyte ratio and histological chorioamnionitis in women who delivered preterm with no clinical signs or symptoms of infection.

  • Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis

    KE Duhig, PT Seed, JE Myers, R Bahl, G Bambridge, S Barnfield, J Ficquet, JC Girling, A Khalil,, AH Shennan, LC Chappell, RM Hunter.
    Accepted 10 June 2019. Published Online 17 July 2019.
    Objective: To calculate the cost-effectiveness of implementing PlGF testing alongside a clinical management algorithm in maternity services in the UK, compared with current standard care.

  • Development and evaluation of a novel Vital Signs Alert device for use in pregnancy in low-resource settings

    Hannah L Nathan, Nicola Vousden, Elodie Lawley, Annemarie de Greeff, Natasha L Hezelgrave, Nicola Sloan, Nina Tanna, Shivaprasad S Goudar, Muchabayiwa F Gidiri, Jane Sandall, Lucy C Chappell, Andrew H Shennan
    Received 9 August 2017. Revised 15 August 2018. Accepted 17 August 2018
    Objective: Haemorrhage, hypertension, sepsis and abortion complications (often from haemorrhage or sepsis) contribute to 60% of all maternal deaths. Each is associated with vital signs (blood pressure (BP) and pulse) abnormalities, and the majority of deaths are preventable through simple and timely intervention. This paper presents the development and evaluation of the CRADLE Vital Signs Alert (VSA), an accurate, low-cost and easy-to-use device measuring BP and pulse with an integrated traffic light early warning system. The VSA was designed to be used by all cadres of healthcare providers for pregnant women in low-resource settings with the aim to prevent avoidable maternal mortality and morbidity.

  • Can a Low-Resource-Use Blood Pressure Device Impact on Global Maternal Mortality?

    Elinor Chloe Baker, Andrew van der Westhuizen, Kate E. Duhig & Andrew Shennan
    Published online: 22 Oct 2010
    Objective and methods: To describe how existing antenatal care systems provide a useful and relevant model through which to evaluate the potential for this initiative to be applied in low-resource settings and to offer opportunities for much needed further research.

  • The BMJ Awards 2020 Entry Form

    Pregnant women can develop pre-eclampsia, a common and potentially serious complication. For the last 100 years, we have relied on measuring blood pressure and dipping their urine for protein. But the clinical presentation is varied, with complications occurring before diagnosis is confirmed. Conversely hypertension or proteinuria can occur without progression to pre-eclampsia.

  • Diagnostic Accuracy of Placental Growth Factor in Women With Suspected Preeclampsia. A Prospective Multicenter Study

    Lucy C. Chappell, PhD; Suzy Duckworth, MBBS; Paul T. Seed, CStat; Melanie Griffin, MBChB; Jenny Myers, PhD; Lucy Mackillop, MA; Nigel Simpson, MBBS; Jason Waugh, MBBS; Dilly Anumba, MD; Louise C. Kenny, PhD; Christopher W.G. Redman, MBChir; Andrew H. Shennan, MD
    Received April 15, 2013; accepted September 3, 2013.

    Methods and Results: In a prospective multicenter study, we studied the diagnostic accuracy of low plasma PlGF concentration (<5th centile for gestation, Alere Triage assay) in women presenting with suspected preeclampsia between 20 and 35 weeks’ gestation (and up to 41 weeks’ gestation as a secondary analysis).

  • Evaluation of a novel vital sign device to reduce maternal mortality and morbidity in low-resource settings: a mixed method feasibility study for the CRADLE-3 trial

    Nicola Vousden , Elodie Lawley, Hannah L. Nathan, Paul T. Seed, Adrian Brown, Tafadzwa Muchengwa, Umesh Charantimath, Mrutyunjaya Bellad, Muchabayiwa Francis Gidiri, Shivaprasad Goudar, Lucy C. Chappell, Jane Sandall, Andrew H. Shennan and on behalf of the CRADLE Trial Collaborative Group
    Received: 4 January 2018 Accepted: 9 April 2018. Published online: 27 April 2018

    Background: The CRADLE-3 trial is a stepped-wedge randomised controlled trial aiming to reduce maternal mortality and morbidity by implementing a novel vital sign device (CRADLE Vital Sign Alert) and training package into routine maternity care in 10 low-income sites. The MRC Guidance on complex interventions proposes that interventions and implementation strategies be shaped by early phase piloting and development work. We present the findings of a three-month mixed-methodology feasibility study for this trial, describe how this was informed by the MRC guidance and the study design was refined.

  • Effect of a novel vital sign device on maternal mortality and morbidity in low-resource settings: a pragmatic, stepped-wedge, cluster-randomised controlled trial

    Nicola Vousden, Elodie Lawley, Hannah L Nathan, Paul T Seed, Muchabayiwa Francis Gidiri, Shivaprasad Goudar, Jane Sandall, Lucy C Chappell, Andrew H Shennan, on behalf of the CRADLE Trial Collaborative Group
    Lancet Glob Health 2019; 7: e347–56

    Background: In 2015, an estimated 303 000 women died in pregnancy and childbirth. Obstetric haemorrhage, sepsis, and hypertensive disorders of pregnancy account for more than 50% of maternal deaths worldwide. There are effective treatments for these pregnancy complications, but they require early detection by measurement of vital signs and timely administration to save lives. The primary aim of this trial was to determine whether implementation of the CRADLE Vital Sign Alert and an education package into community and facility maternity care in lowresource settings could reduce a composite of all-cause maternal mortality or major morbidity (eclampsia and hysterectomy).

  • Evaluation of a novel device for the management of high blood pressure and shock in pregnancy in low-resource settings: study protocol for a steppedwedge cluster-randomised controlled trial (CRADLE-3 trial)

    Hannah L. Nathan, Kate Duhig, Nicola Vousden, Elodie Lawley, Paul T. Seed, Jane Sandall, Mrutyunjaya B. Bellad, Adrian C. Brown, Lucy C. Chappell, Shivaprasad S. Goudar, Muchabayiwa F. Gidiri, Andrew H. Shennan and the CRADLE-3 Trial Collaboration Group
    Nathan et al. Trials (2018) 19:206

    Background: Obstetric haemorrhage, sepsis and pregnancy hypertension account for more than 50% of maternal deaths worldwide. Early detection and effective management of these conditions relies on vital signs. The Microlife® CRADLE Vital Sign Alert (VSA) is an easy-to-use, accurate device that measures blood pressure and pulse. It incorporates a traffic-light early warning system that alerts all levels of healthcare provider to the need for escalation of care in women with obstetric haemorrhage, sepsis or pregnancy hypertension, thereby aiding early recognition of haemodynamic instability and preventing maternal mortality and morbidity. The aim of the trial was to determine whether implementation of the CRADLE intervention (the Microlife® CRADLE VSA device and CRADLE training package) into routine maternity care in place of existing equipment will reduce a composite outcome of maternal mortality and morbidity in low- and middle-income country populations.

  • Development of an accurate oscillometric blood pressure device for low resource settings

    Annemarie de Greeff, Hannah Nathan, Nina Stafford, Bing Liu and Andrew H. Shennan
    Received 10 April 2008 Revised 23 June 2008, Accepted 24 June 2008

    Background: To assess and develop an accurate blood pressure measurement device for use in low resource settings and by untrained staff, according to the World Health Organisation guidelines.

  • Incidence of eclampsia and related complications across 10 low- and middleresource geographical regions: Secondary analysis of a cluster randomised controlled trial

    Nicola Vousden, Elodie Lawley, Paul T. Seed, Muchabayiwa Francis Gidiri, Shivaprasad Goudar, Jane Sandall, Lucy C. Chappell, Andrew H. Shennan, on behalf of the CRADLE Trial Collaborative Group
    Received: November 13, 2018, Accepted: March 5, 2019, Published: March 29, 2019

    Background: In 2015, approximately 42,000 women died as a result of hypertensive disorders of pregnancy worldwide; over 99% of these deaths occurred in low- and middle-income countries. The aim of this paper is to describe the incidence and characteristics of eclampsia and related complications from hypertensive disorders of pregnancy across 10 low- and middleincome geographical regions in 8 countries, in relation to magnesium sulfate availability.

  • Exploring the effect of implementation and context on a stepped-wedge randomised controlled trial of a vital sign triage device in routine maternity care in low-resource settings

    Nicola Vousden, Elodie Lawley, Paul T. Seed, Muchabayiwa Francis Gidiri, Umesh Charantimath, Grace Makonyola, Adrian Brown, Lomi Yadeta, Rebecca Best, Sebastian Chinkoyo, Bellington Vwalika, Annettee Nakimuli, James Ditai, Grace Greene, Lucy C. Chappell, Jane Sandall, Andrew H. Shennan and on behalf of the CRADLE Trial Collaborative Group
    Vousden et al. Implementation Science (2019) 14:38

    Background: Interventions aimed at reducing maternal mortality are increasingly complex. Understanding how complex interventions are delivered, to whom, and how they work is key in ensuring their rapid scale-up. We delivered a vital signs triage intervention into routine maternity care in eight low- and middle-income countries with the aim of reducing a composite outcome of morbidity and mortality. This was a pragmatic, hybrid effectiveness-implementation stepped-wedge randomised controlled trial. In this study, we present the results of the mixed-methods process evaluation. The aim was to describe implementation and local context and integrate results to determine whether differences in the effect of the intervention across sites could be explained.

  • Incidence and characteristics of pregnancyrelated death across ten low- and middle-income geographical regions: secondary analysis of a cluster randomised controlled trial

    N Vousden, E Holmes, PT Seed, MF Gidiri, S Goudar, J Sandall, S Chinkoyo, LY Kumsa, A Brown, U Charantimath, M Bellad, A Nakimuli, B Vwalika, LC Chappell, AH Shennan, on behalf of the CRADLE Trial Collaborative Group
    Accepted 22 April 2020. Published Online 2 June 2020

    Background: The aim of this article is to describe the incidence and characteristics of pregnancy-related death in low- and middleresource settings, in relation to the availability of key obstetric resources.

  • The IC2030 Report. Reimagining global health. 30 high-impact innovations to save lives

    Steve Davis (President and CEO, PATH), Tore Godal (Special Advisor on Global Health, Ministry of Foreign Affairs, Norway), Christopher Elias (President, Global Development Program, Bill & Melinda Gates Foundation), Ariel Pablos-Méndez (Assistant Administrator for Global Health, US Agency for International Development)
    July 2015

    Background: We stand on the cusp of an unprecedented opportunity—the chance to transform health through the power of innovation, ensuring a brighter future for people in every corner of the globe. Advances in science, technology, and health care delivery are already opening the doors of possibility in ways that were previously unimaginable. The United Nations (UN) Millennium Development Goals catalyzed a new global focus on ending preventable maternal and child deaths, goals that have driven unparalleled progress since 2000. Reimagining Global Health, the inaugural report of the Innovation Countdown 2030 initiative, highlights 30 lifesaving innovations with great promise to accelerate that progress over the next 15 years to reach the proposed health targets of the UN Sustainable Development Goals (SDGs).

  • Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial

    Kate E Duhig, Jenny Myers, Paul T Seed, Jenie Sparkes, Jessica Lowe, Rachael M Hunter, Andrew H Shennan, Lucy C Chappell, on behalf of the PARROT trial group
    Lancet 2019; 393: 1807–18. Published Online April 1, 2019

    Background: Previous prospective cohort studies have shown that angiogenic factors have a high diagnostic accuracy in women with suspected pre-eclampsia, but we remain uncertain of the effectiveness of these tests in a real-world setting. We therefore aimed to determine whether knowledge of the circulating concentration of placental growth factor (PlGF), an angiogenic factor, integrated with a clinical management algorithm, decreased the time for clinicians to make a diagnosis in women with suspected pre-eclampsia, and whether this approach reduced subsequent maternal or perinatal adverse outcomes.

  • Accuracy validation of the Microlife 3AS1-2 blood pressure device in a pregnant population with low blood pressure

    Hannah L. Nathan, Annemarie de Greeff, Natasha L. Hezelgrave, Lucy C. Chappell and Andrew H. Shennan
    Received 19 August 2014 Revised 15 April 2015 Accepted 18 April 2015

    Background: To assess the accuracy of the Microlife 3AS1-2 blood pressure (BP) device in pregnant women with low BP to investigate suitability for hypotensive detection in lowincome and middle-income countries.

  • Development of an accurate oscillometric blood pressure device for low resource settings

    Annemarie de Greeff, Hannah Nathan, Nina Stafford, Bing Liu and Andrew H. Shennan
    Received 10 April 2008, Revised 23 June 2008, Accepted 24 June 2008

    Background: To assess and develop an accurate blood pressure measurement device for use in low resource settings and by untrained staff, according to the World Health Organisation guidelines.

  • An accurate semiautomated oscillometric blood pressure device for use in pregnancy (including pre-eclampsia) in a low-income and middle-income country population: the Microlife 3AS1-2

    Hannah L. Nathan, Annemarie de Greeff, Natasha L. Hezelgrave, Lucy C. Chappell and Andrew H. Shennan
    Received 27 March 2014, Revised 13 August 2014, Accepted 19 August 2014

    Background: To assess the accuracy of the Microlife 3AS1-2 blood pressure device in pregnancy and pre-eclampsia in a low-resource setting.

  • Eclampsia among adolescent mothers in low- and middle-Income countriesTitle

    Van der Krogt, L, Ridout, A, Vousden, N, Nathan, H, Seed, P, Sam, B, Momoh, M, Sessay, T, Smart, F, Bellad, M, Vwalika, B, Shennan, A
    Published 26 March 2025

    Objective:Eclampsia among adolescent mothers in low- and middle-Income countries

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Scroll to Top